Skip to main content
Breaking News
Feature Story

Viral crossroads

BioCentury is providing in-depth analysis of the sudden impact of social media on difficult medical and ethical decisions surrounding compassionate access to experimental medicines. See the story from a multitude of angles in our continuing coverage.


Full Article
  • COVER STORY

    Unlocking cancer data

    With upfront buy-in from executive leadership in industry, academia and non-profits, Project Data Sphere for cancer could overcome challenges that have slowed other data-sharing efforts.

  • Blazing a path in data sharing

    The cancer data-sharing group Project Data Sphere met with the Critical Path Institute to learn from the institute's data-sharing initiatives for neurodegenerative diseases.

  • PRODUCT DISCOVERY & DEVELOPMENT

    Family resemblance

    Data reported so far for the most advanced PCSK9 inhibitors look similar, but trials in the LDL-lowering indications where the products will see the earliest uptake are still to come.

  • EMERGING COMPANY PROFILE

    Quantum: Silicon speed

    Quantum Biosystems has joined the single-molecule sequencing race with a solid-state system that could offer improved development timelines over nanopore technologies.

  • FINANCE

    Reasons Unknown

    Whatever caused Kenneth Moch to depart Chimerix as president and CEO, it wasn't stock performance.

  • Reducing the Burden

    In a Guest Commentary, two capital market veterans argue it is time to modify SEC disclosure rules that are not only a burden to young public biotechs, but do little to actually help investors.

  • Lean VC Profile

    Early backing from strategic investors and a string of deals like a new Celgene partnership have given Forma a free hand to build its drug discovery engine without leaning on VCs.

  • Ebb & Flow

    Deerfield's new crossover mandate. Nucana's B may be plenty. SkyPharma's debt riddance. Spinifex's U.S. beachhead. Also: Gilead; Biogen; Agios; Idenix; Puma; Adamas; Celladon, et al.

Compassionate Access

  • COVER STORY

    Pre-EMP-tive strike against GBM

    UCLA researchers have treated glioblastoma in mice by inhibiting EMP2. The findings open up a new indication for spinout Paganini, which has a mAb against the target in development for triple-negative breast cancer.

  • TARGETS & MECHANISMS

    Positioning properdin

    Researchers at the University of Leicester have shown that a recombinant properdin produced in collaboration with The Medicines Co. has markedly higher antibacterial activity than the native protein. The researchers are now working to improve the recombinant protein's activity and homogeneity.

  • Catastrophic vacuolization

    Karolinska Institute scientists have attacked glioblastoma multiforme by inducing an unconventional cell death pathway involving catastrophic vacuolization. The team identified a small molecule that prolonged survival in mouse GBM, but a combination approach with a conventional anticancer agent will likely be necessary in the clinic.

  • TOOLS

    Toxic assets

    A tool for in vivo detection of liver toxicity could represent a substantial improvement over in vitro methods. The litmus test for the Stanford University inventors will be to show that the nanoparticle-based method can detect toxicity in compounds that previously eluded standard analysis and later failed in the clinic.

  • THERAPEUTICS

    This Week in Therapeutics

    Allosteric inhibition of thrombin to prevent blood clots and thrombosis; FXR activation by vertical sleeve gastrectomy to counter obesity; antagonism of HRD1 to treat liver cirrhosis; and more...

  • TECHNIQUES

    This Week in Techniques

    A mouse model for ovarian cancer with pituitary-specific estrogen receptor knockout; CAIX-targeted small molecule-drug conjugates; small molecule inhibitors of microRNA processing; and more...

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.